About

Eric A. Millican, MD, is an Associate Professor in the Department of Dermatology at the University of Utah School of Medicine. He specializes in the prevention, diagnosis, and treatment of skin cancer. He is fellowship-trained in Mohs Micrographic Surgery, a tissue-sparing technique for treating skin cancers with the highest cure rate. His clinical interests include the management of skin cancers in immunosuppressed and transplant patients. Dr. Millican is board certified in Dermatology and Micrographic Dermatologic Surgery and is a Fellow of the American College of Mohs Surgery (ACMS).

Research topics

• Computer Science
• Medicine
• Family medicine
• Internal medicine
• Gerontology
• Medical education
• Pathology

Selected publications

• Creating State-Funded Residency Programs: How They Did It in Rural Indiana.

  PubMed · 2024

  Senior authorCorresponding
  • Computer Science
  • Medical education
  • Medicine
  PublisherOA PDF

• Development of patient decision aids for the treatment of lentigo maligna and low-risk basal cell carcinoma

  Journal of the American Academy of Dermatology · 2022 · 5 citations

  • Medicine
  • Family medicine
  • Internal medicine
  PublisherOA PDFDOI

• Other Skin Cancers

  Holland‐Frei Cancer Medicine · 2022-10-21

  other

  Overview Nonmelanoma skin cancer (NMSC) includes squamous cell carcinoma (SCC), basal cell carcinoma (BCC), Merkel cell carcinoma (MCC), and other premalignant and malignant tumor types. The incidence of NMSC has increased significantly in recent years. These cancers are diverse in their clinical presentation, biology, and capacity to metastasize. Our understanding of the molecular biology of NMSC has grown considerably in recent years, leading to the development of new treatment options. In addition to malignant NMSC, this article will discuss several benign skin tumors that arise due to underlying internal malignancies.

  PublisherDOI

• Use of a Rigid External Bolster for Helical Support During Secondary Intention Healing

  Dermatologic Surgery · 2019-12-03 · 1 citations

  articleSenior author

  *Department of Medicine, Intermountain Medical Center, Salt Lake City, Utah †School of Medicine, University of Utah, Salt Lake City, Utah ‡Department of Dermatology, University of Utah, Salt Lake City, Utah The authors have indicated no significant interest with commercial supporters.

  PublisherDOI

• Opioid Prescribing Patterns After Micrographic Surgery: A Follow-up Retrospective Chart Review

  Dermatologic Surgery · 2018-12-21 · 6 citations

  article

  BACKGROUND: The abuse of opioids has reached epidemic proportions in the United States, and leftover medications are a primary source for nonmedical pain relievers. A past study at the University of Utah showed that micrographic surgeons were likely overprescribing opioids, with 35% of patients receiving a postoperative prescription. OBJECTIVE: To examine the current opioid prescribing habits of the micrographic surgeons at the University of Utah compared with those in 2010. METHODS: Retrospective chart review of the patient records of 4 micrographic surgeons between February and May 2017. RESULTS: Four hundred patient visits were reviewed. An opioid prescription was provided after 12% of encounters, 23% lower than in 2010 (p = .004). Younger patient age, increased number of stages and defect size, repair of the defect, and particular surgeons predicted opioid prescription. CONCLUSION: The percentage of patients who received an opioid prescription after undergoing micrographic surgery at the University of Utah decreased from 35% in 2010 to 12% in 2017. Reports of the minimal need of opioids after micrographic surgery, the authors' past study showing an institutional tendency to overprescribe, and reports of the national opioid epidemic likely all contributed to the decrease in opioid prescriptions at the authors' institution.

  PublisherDOI

• Cosmetic and Functional Outcomes of Second Intention Healing for Mohs Defects of the Lips

  Dermatologic Surgery · 2018-07-12 · 12 citations

  articleSenior author

  BACKGROUND: The lips are a common location for skin cancer and thus for Mohs micrographic surgery (MMS). There are few studies looking at second intention healing of Mohs defects of the lips, and none have used a scar assessment scale. OBJECTIVE: To evaluate the acceptability of second intention healing of the vermilion lips following MMS using a patient questionnaire and the Patient and Observer Assessment Scale (POSAS). METHODS: Eligible patients were found through chart review. A patient questionnaire and the patient scale of the POSAS were performed over the phone. For patients who were able to come to clinic, the observer scale of the POSAS was performed. RESULTS: Forty-seven phone interviews and 21 clinic assessments were performed. Overall, patients noted excellent functional outcomes, and good to excellent cosmetic outcomes, and were satisfied with healing time. There was not a significant difference between the patient and observer total scores (p = .63) or overall scores (p = .59). CONCLUSION: Second intention healing can have satisfactory functional and cosmetic outcomes and healing times with few complications and should be considered for surgical defects on the vermilion lips as large as 2.8 cm even when there is involvement of the cutaneous lip and muscular layer.

  PublisherDOI

• Genetic-based dosing in orthopaedic patients beginning warfarin therapy Running Title: Genetic-Based Warfarin Dose Refinement

  2017-01-01

  article1st authorCorresponding

  High variability in drug response and a narrow therapeutic index complicate warfarin therapy initiation. No existing algorithm provides recommendations on refining the initial warfarin dose based on genetic variables, clinical data, and International Normalized Ratio (INR) values. Our goal was to develop such an algorithm. We studied 92 patients undergoing primary or revision total hip or knee replacement. From each patient we collected a blood sample, clinical variables, current medications, and preand post-operative laboratory values. We genotyped for polymorphisms in the cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase (VKORC1) genes. Using stepwise regression we developed a model for refining the warfarin dose after the third warfarin dose. The algorithm explained four-fifths of the variability in therapeutic dose (Radj of 79%). Significant (P<0.05) predictors were INR value after 3 doses (47% reduction per 0.25 unit rise), first warfarin dose (+7% per 1 mg), CYP2C9*3 and CYP2C9*2 genotype (–38% and –17% per allele), estimated blood loss (interacting with INR3), smoking status (+20% in current smokers), and VKORC1 (–11% per copy of haplotype A). If validated, this model should provide a safer, more effective process for initiating warfarin therapy. For personal use only. on January 1, 2017. by guest www.bloodjournal.org From

  Publisher

• Other Skin Cancers

  Holland‐Frei Cancer Medicine · 2017-02-26

  other

  Overview Several more common types of nonmelanoma skin cancer are presented with attention to etiology and current treatment options.

  PublisherDOI

• Cutaneous lymphoid hyperplasia related to squaric acid dibutyl ester

  Journal of the American Academy of Dermatology · 2011-06-24 · 9 citations

  letterOpen access1st author
  PublisherOA PDFDOI

• Retrospective Review of Temporal Lobe Necrosis Following IMRT for Nasopharyngeal Carcinoma

  International Journal of Radiation Oncology*Biology*Physics · 2009-10-05 · 2 citations

  article1st authorCorresponding
  PublisherDOI

Frequent coauthors

• Payam Tristani‐Firouzi

  9 shared

• Amanda Hedderman

  University of Utah

  9 shared

• Glen M. Bowen

  University of Utah

  9 shared

• Keith L. Duffy

  University of Utah

  9 shared

• Gloria R. Grice

  University of Health Sciences and Pharmacy

  6 shared

• Paul E. Milligan

  BJC HealthCare

  5 shared

• Susan K. Gatchel

  4 shared

• Robert L. Barrack

  4 shared

Awards & honors

• Fellow of the American College of Mohs Surgery (ACMS)
• American Board of Dermatology (Sub: Micrographic Dermatologi…
• American Board of Dermatology